Cambridge, MA-based Ironwood Pharmaceuticals (NASDAQ: [[ticker:IRWD]]) and New York-based Forest Laboratories (NYSE: [[ticker:FRX]]) announced today that they have submitted an application to the FDA for approval of their drug linaclotide, a treatment for irritable bowel syndrome with constipation and chronic constipation.The application includes safety and efficacy data from two long-term safety studies and four placebo-controlled clinical trials. Those four trials involved more than 2,800 patients and showed that linaclotide, Ironwood’s lead drug candidate, provided a statistically significant improvement in abdominal and bowel symptoms when compared against a placebo.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
